National Academies Press: OpenBook
« Previous: Appendix C: Staff and Consultant Biographies
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

Appendix D

Public Meeting Agendas

Committee on Vaccine Research and Development for Advancing Pandemic and Seasonal Influenza Preparedness and Response

First Committee Meeting Agenda

March 8 and 10, 2021
Orientation and Conflict of Interest Discussion: March 8, 7:00–9:30 PM EST
Speaker Session: March 10, 7:00–10:00 AM EST
Planning/Working Session: March 10, 3:30–6:30 PM EST
Virtual

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

Monday, March 8, 2021

7:30–8:30 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

8:30–9:00 PM EST OPEN SESSION

8:30 PM Sponsor Perspective on Charge to the Committee
8:45 PM Q&A for Sponsor

9:00–9:30 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

9:30 PM Adjourn

Wednesday, March 10, 2021

7:00–9:00 AM EST OPEN SESSION

7:00 AM Welcome and Opening Remarks
7:10 AM COVID-19 Response: Lessons Learned
NADINE ROUPHAEL

Department of Medicine, Division of Infectious Diseases

Emory University School of Medicine

7:30 AM Discussion with Committee
7:45 AM Regulatory Pathways in the United States to Facilitate Vaccine Availability
PETER MARKS

Center for Biologics Evaluation and Research

U.S. Food and Drug Administration

8:00 AM Discussion with Committee
8:10 AM Break
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
8:15 AM Overview of the Influenza Vaccines R&D Roadmap and the Universal Influenza Vaccine Technology Landscape
JULIE OSTROWSKY

Center for Infectious Disease Research and Policy

University of Minnesota

8:40 AM Discussion with Committee
8:55 AM Break

9:00–10:00 AM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

10:00 AM Adjourn Morning Session

Wednesday, March 10, 2021

3:30–6:30 PM EST CLOSED SESSION

Second Committee Meeting

March 30, 2021
3:00–6:00 PM EST
Virtual

March 30, 2021

3:00–4:30 PM EST OPEN SESSION

3:00 PM Welcome, Review of Previous Session
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
3:10 PM Broadly Protective and Universal Influenza Virus Vaccines in Development
FLORIAN KRAMMER

Professor in Vaccinology

Department of Microbiology

Icahn School of Medicine at Mount Sinai

3:25 PM Discussion with Committee
3:35 PM Perspective on Lessons from the COVID-19 Vaccine Experience
BARNEY GRAHAM

Deputy Director, Vaccine Research Center

Chief, Viral Pathogenesis Laboratory and Translational Science Core

National Institutes of Health

3:50 PM Discussion with Committee
4:00 PM Vaccinating Against Influenza Viruses: Can New Memory Be Induced When Old Memory Is Recalled
ANNETTE FOX

Senior Research Scientist

World Health Organization Collaborating Centre for Reference and Research on Influenza

University of Melbourne

4:15 PM Discussion with Committee
4:25 PM Break, End of Open Session

4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

Third Committee Meeting

April 15, 2021
3:00–6:00 PM EST
Virtual

April 15, 2021

3:00–4:15 PM EST OPEN SESSION

3:00 PM Welcome, Review of Previous Session
3:10 PM Overview of Novel Platforms in Influenza Vaccine and Integrating Lessons from COVID-19
REBECCA COX

Professor of Medical Virology and Head of the Influenza Centre

University of Bergen

3:25 PM Discussion with Committee
3:35 PM Lessons Learned from COVID-19 Vaccine Development
MELANIE SEVILLE

Director of Vaccine Development

Coalition for Epidemic Preparedness Innovations

3:50 PM Discussion with Committee
4:10 PM Break, End of Open Session
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

4:15–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Fourth Committee Meeting

April 28, 2021
3:00–6:00 PM EST
Virtual

April 28, 2021

3:00–3:20 PM EST CLOSED SESSION

3:20–4:30 PM EST OPEN SESSION

3:20 PM Introduction to Open Session
3:30 PM Overview of Vaccine Clinical Trials in Lower- and Middle-Income Countries
MILAGRITOS TAPIA

Professor of Pediatrics and Medicine

University of Maryland at Baltimore

3:45 PM Discussion with Committee
4:00 PM Influenza Vaccines in LMICs: Manufacturing and Feasibility Considerations
KATHY NEUZIL

Director, Center for Vaccine Development

University of Maryland School of Medicine

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
4:15 PM Discussion with Committee
4:25 PM Break, End of Open Session

4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Fifth Committee Meeting

May 12, 2021
8:00–11:00 AM EST
Virtual

May 12, 2021

8:00–9:30 AM EST OPEN SESSION

8:00 AM Introduction to Open Session
8:10 AM Lessons from COVID-19 for Influenza Preparedness
JEROME KIM

Director General

International Vaccine Institute

8:25 AM Discussion with Committee
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
8:35 AM Understanding Vaccine Effectiveness: Lessons from COVID-19 and Applications for Influenza
BEN COWLING

Professor of Epidemiology and Biostatistics

School of Public Health

The University of Hong Kong

8:50 AM Discussion with Committee
9:00 AM Successes and Challenges in Monitoring Vaccine Safety in the United States
GRACE LEE

Professor of Pediatrics

Stanford University School of Medicine

9:30 AM Break, End of Open Session

9:30–11:00 AM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Sixth Committee Meeting

May 26, 2021
3:00–6:00 PM EST
Virtual

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

May 26, 2021

3:00–4:30 PM EST OPEN SESSION

3:00 PM Welcome, Review of Previous Session
3:05 PM Successes in Technology Transfer and Manufacturing Partnerships: Lessons from COVID-19 and Applications for Influenza
MARIA ELENA BOTTAZI

Associate Dean and Professor

Baylor College of Medicine

3:15 PM Discussion with Committee
3:25 PM Manufacturing Science of Influenza Vaccine Research and Development
ROBERT JOHNSON

Director, Influenza and Emerging Infectious

Diseases Division and COVID-19 Incident Manager

Biomedical Advanced Research Development Authority

3:35 PM Discussion with Committee
3:45 PM Developing Vaccines in the Era of Genomics
RINO RAPPUOLI

Chief Scientist and Head of External Research and Development

GlaxoSmithKline

3:55 PM Discussion with Committee
4:05 PM Manufacturing Science of Influenza Vaccine R&D: Mind the Adjacencies
DAVID KASLOW

Chief Scientific Officer

PATH

4:15 PM Discussion with Committee
4:30 PM Break, End of Open Session
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

4:30 PM–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Seventh Committee Meeting

June 10, 2021
3:00–6:00 PM EST
Virtual

June 10, 2021

3:00–4:30 PM EST OPEN SESSION

3:00 PM Welcome
3:10 PM Opening Remarks by Joshua Sharfstein
3:15 PM Key Considerations for Vaccine Research and Development
PHIL DORMITZER

Vice President and Chief Scientific Officer: Viral Vaccines

Pfizer Inc.

3:30 PM Key Considerations for Vaccine Research and Development
RITA HELFAND
Chair

World Health Organization Global Advisory

Committee for Vaccine Safety

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
3:25 PM Key Considerations for Vaccine Research and Development
NICOLE LURIE

Director, Strategic Advisor to the Chief Executive Officer

Coalition for Epidemic Preparedness Initiatives

3:30 PM Panel: Regulatory Science of Vaccine Development
4:30 PM Break, End of Open Session

4:30–6:00 PM EST CLOSED SESSION—COMMITTEE MEMBERS ONLY

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×

This page intentionally left blank.

Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page143
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page144
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page145
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page146
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page147
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page148
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page149
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page150
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page151
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page152
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page153
Suggested Citation:"Appendix D: Public Meeting Agendas." National Academies of Sciences, Engineering, and Medicine and National Academy of Medicine. 2022. Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19. Washington, DC: The National Academies Press. doi: 10.17226/26282.
×
Page154
Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response: Lessons from COVID-19 Get This Book
×
Buy Paperback | $50.00 Buy Ebook | $40.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The global response to COVID-19 has demonstrated the importance of vigilance and preparedness for infectious diseases, particularly influenza. There is a need for more effective influenza vaccines and modern manufacturing technologies that are adaptable and scalable to meet demand during a pandemic. The rapid development of COVID-19 vaccines has demonstrated what is possible with extensive data sharing, researchers who have the necessary resources and novel technologies to conduct and apply their research, rolling review by regulators, and public-private partnerships. As demonstrated throughout the response to COVID-19, the process of research and development of novel vaccines can be significantly optimized when stakeholders are provided with the resources and technologies needed to support their response.

Vaccine Research and Development to Advance Pandemic and Seasonal Influenza Preparedness and Response focuses on how to leverage the knowledge gained from the COVID-19 pandemic to optimize vaccine research and development (R&D) to support the prevention and control of seasonal and pandemic influenza. The committee's findings address four dimensions of vaccine R&D: (1) basic and translational science, (2) clinical science, (3) manufacturing science, and (4) regulatory science.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!